Unusual 11 Mid-Day Movers 10/22: UAUA, CHRW, EEV, CRI Higher; DVAX, CVH, KND, SNDK Lower

Dynavax (NASDAQ: DVAX) 78.1% LOWER; The FDA has advised Dynavax and Merck that the balance of risk versus potential benefit no longer favors continued clinical evaluation of HEPLISAV in healthy adults and children. The FDA has also advised the companies that there may be potential for an acceptable risk versus benefit profile for HEPLISAV in patients with renal failure, and requested additional information from the companies before considering further pursuit of clinical studies in those patients. Dynavax and Merck are evaluating the FDA's response in considering next steps. In the meantime, the clinical hold on the two U.S. IND